Cancer Diagnostics Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

Cancer is one of the leading causes of mortality worldwide, and its incidence is alarmingly on the rise, driving market growth. According to the International Agency for Research on Cancer (IARC), there were an estimated 20 million new cases of cancer and 9.7 million deaths. Currently, approximately 53.5 million people are living five years after a cancer diagnosis. About 1 in 5 individuals will develop cancer at some point in their lifetime. As a result, healthcare professionals are focusing on developing effective treatments and researching responses to reduce the prevalence of the disease. Early detection significantly improves the success rates of treatment regimens. Consequently, healthcare institutions and companies are promoting routine screenings through targeted awareness campaigns.

Growth Driver in the Cancer Diagnostics Market

Rising Cancer Prevalence

Population concern is the rising number of cancer patients across the global market, which is the key driver of the growth of the cancer diagnostics industry. Cancer incidence also increases with age, and due to factors, such as smoking, poor diet, and lack of physical activity, the threat of cancer continues to grow, making it increasingly necessary to have efficient diagnostic methods and solutions. This means early intervention is critical in improving treatment and survival, leading to governments and other players in health care investing in diagnostics. People living with cancer are always encouraged to undertake screening programs, imaging tests, and biomarker diagnostics, which expounds this demand. It is estimated that in 2022, close to 20 million new cancer diagnoses were recorded, and this is estimated to reach 29.9 million by the year 2040. Demographer Nigel GCELL reports that by 2050, the number of affected cases will be 35 million.

Technological Advancements in Diagnostics

Liquid biopsies, NGS, and other imaging technologies are the new trends shaping the cancer diagnostics market. These modern technologies suggest more accurate, invasive, and faster approaches to diagnosing cancer and its types and stages. Besides, using a massive amount of medical imaging and genetic information, AI and machine learning algorithms improve the accuracy of the diagnosis. With technological advancements, especially the affordability and availability of these machines, these markets tend to grow significantly since patients are treated according to their needs. In turn, patients have better results. In Sept 2024, through the further development of its digital pathology open environment, more than 20 advanced AI algorithms from eight new collaborators were added. Such collaborations include strategic partnerships where the primary intent focuses on assisting pathologists and scientists who work within the context of cancers through AI technologies.

Government Initiatives and Funding

Support from the Government and adequate funding facilities for cancer diagnostics are the key factors fueling the market's growth. Most nations are designing national screening programs and policies in an attempt to decrease the mortality rates of cancer. The government and other healthcare facilities involved in the care of the population are expanding their funding for research to improve diagnostic techniques and to increase the availability of the diagnostic stage. Cancer diagnostic technologies contain grants, subsidies, and private corporate and public health collaborations driving innovation. These actions raise the availability of diagnostics and the understanding of the need for early diagnosis, contributing to the market's growth. In February 2024, the government revealed a new Children and Young People Cancer Taskforce to enhance treatment, detection, and research about children’s cancer.

Challenges in the Cancer Monitoring Market

High Cost of Diagnostic Procedures

Cancer diagnostic technologies, such as advanced imaging and molecular testing, are often expensive, limiting their accessibility for patients in low-income regions. The high costs include equipment, reagents, and skilled personnel, making routine screenings and early detection difficult. This financial barrier is particularly significant in underdeveloped healthcare systems, where affordability and insurance coverage are inadequate. Efforts to reduce costs through innovation and public health initiatives are crucial to improving access.

Limited Access to Advanced Technologies

Access to cutting-edge diagnostic tools is restricted in many regions due to inadequate infrastructure and trained professionals. Rural and underserved areas often lack sophisticated imaging facilities, laboratories, and expertise in molecular diagnostics. This limitation delays accurate diagnosis and treatment, contributing to poorer patient outcomes. Expanding healthcare infrastructure, telemedicine, and training programs for medical professionals are essential to bridging this gap and ensuring equitable access to cancer diagnostics globally.

Breast cancer diagnostics market

Breast cancer diagnostics claim one of the vast shares of the global market. This is due to the high prevalence and mortality rates associated with the disease. According to the World Health Organization (WHO), there have been 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. Routine screenings like mammograms are widely recommended for early detection, propelling demand for diagnostic equipment, including imaging modalities and biopsy strategies. Further, advancements in customized medicinal drugs and genetic testing augment the breast cancer diagnostics market, allowing tailored remedy processes. With a growing emphasis on early intervention and improved survival prices, breast cancer diagnostics stay a cornerstone in oncology practice.

Cancer Imaging Tests Market

Imaging test types represent one of the most significant global cancer diagnostics market segments. This is due to their pivotal function in detecting, staging, and tracking cancers. Modalities like MRI, CT, PET, and ultrasound offer designated anatomical and functional data, aiding in precise analysis and remedy planning. With improvements in imaging technology like contrast-enhanced and molecular imaging, these assessments offer an increasing number of accurate and complete evaluations of tumors. As healthcare structures prioritize early detection and customized remedies, imaging test types remain fundamental to cancer diagnostics.

Cancer Diagnostic Centers Market

Diagnostic centers have emerged as one of the dominant segments in the global cancer diagnostics market. This is because of their specialized know-how and comprehensive offerings. These facilities provide diagnostic assessments, which include imaging, biopsies, and laboratory analyses, ensuring correct and well-timed cancer detection. With their cutting-edge device and experienced personnel, diagnostic facilities offer a centralized hub for patients and healthcare specialists seeking efficient and thorough cancer diagnostics.

United States Cancer Diagnostics Market

The United States can potentially preserve its lead in the global market during the projection period. This is due to the developing cancer burden and the growing awareness of clinical device organizations on developing novel diagnostic instruments that can hit upon cancer. Further, the initiatives the authorities took in this area are anticipated to boost the market increase. For example, in 2022, President Biden announced a renewed effort for the Cancer Moonshot to lessen cancer deaths by 50% in 25 years while enhancing the lives of people with cancer and survivors. So, the government helps cancer diagnosis drives, which might be believed to contribute to the increase of the global cancer diagnostics market.

Germany Cancer Monitoring Market

Currently, Germany has a growing market for cancer monitoring owing to an increased rate of cancer diagnosis and growing demand for diagnosis in their early stages. Investment in knowledge through funding of medical research and the development of modern forms of healthcare in Germany has made it possible to make frequent and efficient use of new diagnostic tools like liquid biopsies, NGS, and advanced image studies. The growing awareness campaigns by governments and nationally sanctioned cancer detection programs, especially breast, colon, and lung cancer, also boost market growth. Furthermore, the increasing importance of personalized medicine and individualized diagnostics brings continuous development of cancer diagnosis in Germany. In 2022, Germany has been diagnosed with breast cancer 75,000, bowel cancer 62,000, and prostate cancer 65,000, new cases.

 India Cancer Diagnosis Market

The Indian cancer diagnosis market is experiencing significant growth due to the rising incidence of cancer and increased awareness about early detection. Advancements in technology, such as molecular diagnostics and imaging techniques, are enhancing diagnostic accuracy and speed. Government initiatives and collaborations with private organizations also foster research and development in this sector. Moreover, the growth of healthcare infrastructure, including cancer centers and laboratories, is improving accessibility to diagnostic services. As patients seek timely diagnosis for better treatment outcomes, the market is expected to expand further, attracting investments and innovations in cancer detection methodologies.

Brazil Cancer Treatment Market

The Brazil cancer treatment market is experiencing significant growth, driven by increasing cancer incidence and advancements in diagnostic technologies. Rising awareness about early detection and improved healthcare infrastructure contribute to this trend. Key players in the market are focusing on innovative solutions, including molecular diagnostics and imaging techniques, to enhance accuracy and speed in cancer detection. Government initiatives and collaborations with international organizations further propel this sector's development. As a result, Brazil is positioning itself as a vital hub for cancer treatment in Latin America, attracting investments and fostering research to improve patient outcomes and treatment options.

Saudi Arabia Cancer Diagnostics Market

The Saudi Arabia-based cancer diagnostics market is expanding due to rising cancer incidence and increased healthcare expenditure. The Kenyan government’s Vision 2030 documents focus on enhancing healthcare services, including early cancer detection and better diagnostic techniques. Recently, Saudi Arabia has been increasing investment in healthcare facilities and new or improved diagnostic technologies, including enhanced imaging studies and molecular diagnostics, to name a few. Community awareness and education and national cancer testing initiatives, especially for breast and colon cancer, add to the market. Other drivers regarding the growth of the cancer diagnostics market include the increasing use of personalized medicine and increased emphasis on better patient outcomes. Cancer incidence for new cases will likely rise from 27,885 in 2020 to 60,429 in 2040.

Key Players

In the global cancer diagnostics market, prominent players include Illumina, Abbott Laboratories, Thermo Fisher Scientific, Inc., QIAGEN N.V., Roche Holding AG, Pfizer, Inc., Koninklijke Philips N.V., and bioMérieux.

In April 2023, Quest Diagnostics acquired Haystack Oncology in an all-cash deal to expand MRD testing services focusing on colorectal, breast, and lung cancers. The company aims to improve patient outcomes by detecting MRD early after treatment.

In June 2023 - Blue Earth Diagnostics received FDA approval for POSLUMA, a high-affinity rh-PSMA-targeted PET imaging agent, for prostate cancer detection and localization. The innovative radio hybrid technology provides accurate imaging and potential therapeutic applications.

Application – Market breakup in 12 viewpoints:

1.    Breast Cancer
2.    Colorectal Cancer
3.    Cervical Cancer
4.    Lung Cancer
5.    Prostate Cancer
6.    Skin Cancer
7.    Blood Cancer
8.    Kidney Cancer
9.    Liver Cancer
10.    Pancreatic Cancer
11.    Ovarian Cancer
12.    Others

Test Type – Market breakup in 6 viewpoints:

1.    Tumor Biomarkers Tests
2.    Imaging
3.    Biopsy
4.    Liquid Biopsy
5.    Immunohistochemistry
6.    In Situ Hybridization

End-User – Market breakup in 4 viewpoints:

1.    Diagnostic Centers
2.    Hospitals and Clinics
3.    Research Institutes
4.    Others

Country – Market of 25 Countries:

1.    North America

1.1    United States
1.2    Canada

2.    Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherlands
2.8    Turkey

3.    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4.    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia
5.2    UAE
5.3    South Africa

All the Key players have been covered from 3 Viewpoints:

•    Overview
•    Recent Development
•    Revenue Analysis

Company Analysis:

1.    llumina
2.    Abbott Laboratories
3.    Thermo Fisher Scientific, Inc.
4.    QIAGEN N.V.
5.    Roche Holding AG.
6.    Pfizer, Inc.
7.    Koninklijke Philips N.V.
8.    bioMérieux

Report Details: